iJRASET
International Journal For Research in Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** IV **Month of publication:** April 2025

DOI: https://doi.org/10.22214/ijraset.2025.68559

www.ijraset.com

Call: 08813907089 | E-mail ID: ijraset@gmail.com

International Journal for Research in Applied Science & Engineering Technology (IJRASET)
ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com


Biosimilars: The Future of Biologic Therapy

Patil Prasad S.[1], Vadnere Asmita G.[2]
Matoshri College of Pharmacy, India

Abstract: ***Chronic diseases are continuing to rise globally, emphasizing the need for patients to have access to safe and effective treatments. Biologics represent a unique and powerful class of medications that have significantly changed how doctors manage conditions like cancer, diabetes, and autoimmune diseases. These treatments have led to outstanding patient outcomes—for example, biologics have halved the mortality rate for non-Hodgkin's lymphoma. Presently, there are over 200 biologics and vaccines available worldwide, most of which are therapeutic proteins—lab-engineered proteins used in medicine, with insulin being the first developed. The field is expanding rapidly, with more than 900 biotechnology medicines and vaccines currently under development. Unlike traditional "small-molecule" drugs such as Aspirin, biologics are much more complex. They are derived from living organisms and cannot be produced solely through chemical synthesis. These drugs go by various terms including biologics, biologic therapies, biologic agents, BRMs (biological response modifiers), or immunotherapies.***


Biosimilars, also known as follow-on biologics or subsequent entry biologics, are highly similar versions of original biologic medicines that have lost their patent exclusivity. They offer more affordable treatment options and can stimulate competition in the biologic drug market. The original biologic is typically referred to as the reference, originator, or innovator product. A biosimilar must prove it has no clinically significant differences from its reference product in terms of safety, purity, and effectiveness. While they usually share the same primary structure and most molecular traits, slight variations in non-active components may occur.It's important not to confuse biosimilars with generic drugs. Generics are exact chemical copies of brand-name drugs, identical in active ingredients, dosage, strength, route of administration, and performance—they are "bioequivalent." Biosimilars, on the other hand, are "highly similar," not identical, due to being made from living cells—this distinction is crucial. Modern biologic drugs have shown they can significantly improve patient health, but access remains limited—mainly due to high costs. As many well-known biologics are approaching the end of their patent and exclusivity periods, biosimilars are becoming a promising alternative. These treatments are especially appealing because they are generally more affordable, which can enhance access and offer broader benefits to patients, healthcare providers, and the healthcare system as a whole.


Keyterms: Biopharmaceutical Industry; Biologic Medicines; Biosimilar Products; Pharmaceutical Exports.



©IJRASET: All Rights are Reserved

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com





I. INTRODUCTION

Biosimilars are drugs that closely resemble an FDA-approved biologic, often referred to as the reference biologic. The Central Drug Standard Control Organization (CDSCO) defines biosimilars as "similar biologic products that are similar in terms of quality, safety, and efficacy to an approved reference biologic product based on comparability". They are developed using the same or comparable methods as the reference biologic and have been shown to offer similar safety and effectiveness, while also presenting benefits such as reduced cost and enhanced accessibility.Biologics are created with a range of biotechnological methods—including recombinant DNA technology, controlled gene expression, and antibody technology—and are derived from natural sources such as human, animal, or microbial cells. These biologics help to halt disease progression, alleviate symptoms, and improve patients' quality of life. As some of the most widely purchased drugs both globally and in the United States, their high cost, however, renders them unaffordable for many, particularly in developing countries where health insurance is not widespread and poverty is prevalent.

Unlike generic drugs, biosimilars differ significantly in molecular structure, size, complexity, and production costs. In addition to being more expensive and challenging to manufacture than traditional small-molecule generics, biosimilars require higher research and development expenditures. Although clear guidelines for developing and marketing biosimilars in India were not available initially, the country approved its first biosimilar—a Hepatitis B vaccine—in 2000. Even though India was among the early adopters of the term "biosimilars or similar biologics," the approval process for these drugs is more rigorous, demanding more extensive data than that required for other generic medications. Since then, numerous biopharmaceutical companies in India have successfully developed and introduced biosimilars.

India represents a major market for biologics, and the demand for biosimilars is expected to rise in the coming years. As the patent protection for original biologic drugs expires, it opens the door for other companies to enter the market with biosimilar alternatives.More than 100 Indian biopharmaceutical companies, alongside major strategic collaborations, are pooling their expertise and resources to develop, manufacture, and commercialize biosimilar products. Both domestic and international players are uniting to navigate the complex regulatory environment, share research capabilities, and benefit from each other's specialized knowledge.As more biosimilars are evaluated and released onto the market, new challenges have surfaced that require ongoing oversight and modifications to the regulatory framework. The continuously evolving landscape of biosimilars calls for a proactive approach to effectively address these emerging hurdles.To improve the affordability and accessibility of advanced treatments, the Indian government, together with regulatory authorities such as the CDSCO and the DBT, has developed thorough guidelines for the development, approval, and commercialization of biosimilars. Consequently, India's biosimilar sector is experiencing rapid growth, driven by both regulatory progress and technological advancements.

A. Official Definitions of Biosimilars from the three Organizations

European Medicines Agency (EMA): A biosimilar is a type of biological drug designed to closely resemble an already authorized biological medicine, known as the reference product. Once approved, any slight variations between the biosimilar and its reference medicine are confirmed to have no impact on safety or effectiveness.


U.S. Food and Drug Administration (FDA): A biosimilar is a biological product that closely matches a previously approved biological medicine in the U.S., with only minor differences in non-active components. It must show no significant differences in safety, purity, or potency compared to the original product.

World Health Organization (WHO): A biosimilar is a biotherapeutic product that demonstrates similarity in quality, safety, and effectiveness to an already licensed reference biotherapeutic medicine.

©IJRASET: All Rights are Reserved

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

II. PRINCIPLES OF BIOSIMILARS



A. Authorities for Biosimilar Approval

The following is the list of primary competent authorities responsible for biosimilar approval in India:-

Institutional safety committee	•IBSC is responsible for ensuring biosafety on-site, along with an initial review of applications to be recommended to RCGM.
Review committee on Genetic Manipulation (RCGM)	•RCGM is responsible for authorizing the conducts of research and development, exchange of genetically engineered cell banks for the purpose of research and development, and review of data up to preclinical evaluation
Genetic Engineering Appraisal Committee (GEAC)	•GEAC functions under the Ministry of Environment and Forests (MoEF) as a statutory body for the review of applications and approval of activities where final drug products contain genetically modified organisms/living modified organisms.
Central Drugs Standard Control Organization (CDSCO)	•CDSCO is responsible for clinical trial approval and permission for manufacturing and marketing.

©IJRASET: All Rights are Reserved

B. Approved Biosimilars in India

Name of the product	Active Compound	Therapeutic Area	Approval/ Launch Date	Company
Biovac-B	Hepatitis B vaccine	Hepatitis	2000	Wockhardt
Basalog	Insulin Glargine	Diabetes	2000	Biocon
Erykine/Epofit	epoetin alfa	Cancer, Chronic Kidney failure, Anaemia	2005	Intas Pharmaceuticals
Filgrastim	filgrastim	Neutropenia	2013	Cadila Pharmaceutical
Cizumab	bevacizumab	Colorectal cancer	2016	Hetero
Krabeva	bevacizumab	Brain cancer, Metastatic colorectal cancer, lung cancer, cervical cancer, Kidney cancer, Ovarian cancer	2017	Biocon
Fesoteroterodine Fumarate Exteneded Release	fesoterodine fumarate	overactive bladder syndrome	2023	Dr. Reddy's Laboratories (UK) Ltd
Crisabrole Ointment 2%	crisaborole	atopic dermatitis	2023	Anacor Pharmaceuticals

III. APPROVAL PROCESS OF BIOSIMILARS

A. Biosimilar Approval Process: Overview

The approval of biosimilars involves a rigorous, step-by-step evaluation by regulatory authorities to ensure they are safe, effective, and of high quality.

Regulatory Framework

1. Regulatory Agencies
    - Major agencies involved include:
        - FDA (U.S. Food and Drug Administration)
        - EMA (European Medicines Agency)
        - CDSCO (Central Drugs Standard Control Organization, India)
2. Guidelines and Regulations
    - Agencies provide specific guidance documents outlining requirements for biosimilar development, including scientific and regulatory expectations.

Approval Process

1. Pre-IND Meeting
    - Sponsors meet with the regulatory agency to discuss development plans, study designs, and regulatory expectations.
2. IND Submission (Investigational New Drug)
    - Submitted to initiate clinical trials.
    - Includes data on:
        - Chemistry
        - Manufacturing processes
        - Controls (CMC information)
3. Clinical Trials
    - Conducted to demonstrate:
        - Safety
        - Efficacy
        - Pharmacokinetics (PK) and pharmacodynamics (PD), if applicable
    - Typically includes comparative studies with the reference product.
    -

4. BLA Submission (Biologics License Application)
    - Comprehensive dossier containing:
        - Clinical trial results
        - CMC data
        - Nonclinical data (if required)
        - Evidence of biosimilarity
5. Regulatory Review
    - The agency reviews all submitted data to ensure the biosimilar meets the required standards.
6. Approval
    - Granted if the product is demonstrated to be biosimilar, with no clinically meaningful differences from the reference product.


Key Considerations

1. Biosimilarity
    - The biosimilar must closely match the reference product in:
        - Structure
        - Function
        - Clinical performance
2. Safety and Efficacy
    - Must be demonstrated through well-designed clinical studies.
3. Manufacturing and Quality Control
    - Processes must be robust, consistent, and compliant with Good Manufacturing Practices (GMP).

Post-Approval Requirements

1. Post-Marketing Surveillance (Pharmacovigilance)
    - Ongoing monitoring of:
        - Adverse events
        - Long-term safety and effectiveness
2. Labeling and Packaging
    - Must be accurate and comply with local regulatory standards.
    - Clearly state biosimilar status and reference product information.

B. Approval Procedure for biosimilars




ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com


IV. DEVELOPMENT PROCESS OF BIOSIMILARS

The development of a biosimilar includes analyzing the reference biologic, creating a manufacturing process, performing thorough analytical and clinical studies to prove similarity, and submitting a regulatory application to confirm biosimilarity—rather than proving safety and efficacy independently.

The following flow chart shows the process of development of biosimilars:-





A. Manufacturing Procedure of Biosimilars



©IJRASET: All Rights are Reserved

B. Steps involved in Manufacturing Process





A. Potential Concern

There 4 major concerns as follows:

1. Safety
2. Substitution
3. Naming
4. Labeling

V. THERAPEUTIC PROFILE

Biopharmaceutical products and medicines derived from biological agents include:

- Insulin used in managing diabetes
- Vaccines for disease prevention, such as flu or shingles
- Hormones for treating hormonal imbalances or deficiencies, like growth hormone issues
- Monoclonal antibodies for treating conditions like cancer and autoimmune disorders
- Blood-based therapies and transfusions, including those used for hemophilia
- Immunomodulators that help balance the immune system, such as beta-interferon for multiple sclerosis
- Enzymes that help dissolve blood clots
- Botox, which is used for both skin-related and neurological conditions.

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

A. Use of Biologics in Cancer Treatment

In cancer care, biologic therapies play an important and sometimes multifaceted role in treatment plans. These agents, such as trastuzumab, may be used to directly target cancer or to manage side effects of other treatments—like using erythropoietin to address low blood cell counts. A patient might receive one biologic or a combination of several, and they can also be administered alongside other treatments like chemotherapy, radiation, or surgery.

Biologics can be delivered through various methods, including injections under the skin, into veins, or directly into organs or body cavities using specialized procedures.Certain biologic treatments actually harness the immune system—such as vaccines or modified bacteria designed to stimulate an immune attack on cancer cells. These types of therapies, often grouped under "immunotherapy" or "biological response modifier therapy," work by activating the immune system rather than directly targeting cancer cells.

B. Examples of Various Types of Biologics Used in Cancer Treatment:

- Monoclonal antibodies (MoAbs)
- Cytokines**,** including Interferons (IFNs), Interleukins (ILs), and Hematopoietic Growth Factors
- Colony-Stimulating Factors (CSFs)
- Cancer Vaccines
- Bacillus Calmette-Guérin (BCG) therapy

VI. BIOLOGICS VS BIOSIMILARS VS GENERICS

A. Biologics

- Origin: Derived from living sources such as cells, tissues, or microorganisms.
- Composition: Consist of large, complex molecules.
- Examples: Include vaccines, monoclonal antibodies, and growth hormones.
- Production: Involves advanced biotechnological methods.
- Expense: Typically very costly.
- Medical Use: Employed in the treatment of cancers, autoimmune disorders, and chronic inflammation.

B. Biosimilars

- Origin: Also developed using living organisms, closely resembling the original biologic.
- Composition: Comparable, but not exactly the same, as the original biologic.
- Examples: More affordable alternatives to biologics like Enbrel and Humira.
- Production: Made using processes similar to those used for biologics.
- Expense: Less expensive than biologics, but pricier than generic drugs.
- Regulation: Must undergo strict evaluation by regulatory agencies (e.g., FDA) to confirm similarity.
- Medical Use: Designed to treat the same diseases as their biologic counterparts.

C. Generics

- Origin: Created through chemical synthesis.
- Composition: Made up of simple, small molecules.
- Examples: Inexpensive versions of branded drugs like ibuprofen and amoxicillin.
- Production: Uses straightforward chemical manufacturing.
- Expense: Generally the least expensive option among drug types.
- Regulation: Must pass thorough regulatory checks to ensure they match the original drug in effectiveness and safety.
- Medical Use: Intended for the same health conditions as the original brand-name drug.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

HOW ARE BIOLOGIC MEDICINES DIFFERENT?

Small Molecule Drugs (example: acetaminophen)	Biologics (example: trastuzumab (Herceptin)
Generally low molecular weight	Generally high molecular weight
Often an oral solid (tablet or pill form)	Often an injection or IV infusion
Usually dispensed by retail pharmacies	Often dispensed by physicians or hospitals
Usually organic or chemically synthesized	Made with/from live cells/organisms → inherent & contamination risk
Fewer critical processing steps	Many critical processing steps
Well-characterized	Less easily characterized
Known structure	Structure may or may not be completely defined or known.
Homogeneous drug substance (same throughout)	Heterogeneous mixtures →may include variants
Usually not immunogenic	Often immunogenic

VII. CURRENT STATUS OF BIOSIMILARS IN INDIA

India has developed a thriving biosimilar ecosystem, positioning its pharmaceutical companies as global leaders in the biosimilar market. Notably, India approved its first biosimilar in 2000—well before similar approvals in the United States and Europe. This first biosimilar, used to treat hepatitis B, was introduced despite the absence of specific regulatory guidelines for biosimilar development and marketing at the time.

Since then, numerous biosimilars have been developed and launched in India by various biopharmaceutical companies.In a significant milestone, an Indian biopharmaceutical company recently received approval from the USFDA to market its novel biologic in the United States. Among these achievements, Herceptin (with the active ingredient trastuzumab)—used in treating certain breast and stomach cancers—stands out as the first biologic developed by an Indian manufacturer to receive FDA approval for marketing in the U.S.

Indian pharmaceutical companies are actively taking strategic steps to expand their role in the manufacturing and marketing of biosimilars, aiming to tap into the vast potential of this sector. In India, biosimilars approved and widely used include vaccines, monoclonal antibodies, insulin, and recombinant proteins. The country has earned the distinction of being the world's second-largest supplier of vaccines. Additionally, a diverse range of biosimilars has been approved in India for the treatment of various diseases.

Indian pharmaceutical companies hold immense potential in the global biosimilar market, often outpacing competitors due to several strategic advantages. India has emerged as a key player in the biosimilar industry, backed by the highest number of USFDA-approved manufacturing facilities outside the United States. The country's expanding clinical trials and research capabilities further strengthen its position.

Additionally, low-cost infrastructure, a highly educated population, and a growing pool of skilled professionals create an ideal ecosystem for navigating this complex and evolving sector. However, the absence of well-defined regulatory guidelines for biosimilar approval in India poses a significant challenge. To elevate India's standing in this competitive landscape and establish it as a global leader in biosimilar production, the immediate development and implementation of robust regulatory standards is essential.

©IJRASET: All Rights are Reserved

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com




Fig. Market Size for Biosimilars in India




Fig. Biosimilar Pipelines for Indian Pharmaceutical Companies

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

A. Challenges Faced by the Biosimilar Pharmaceutical Industry

The global regulatory landscape for pharmaceuticals is becoming increasingly stringent. To remain competitive in the international market, the Indian pharmaceutical industry must establish a robust and transparent regulatory framework. Currently, however, the sector faces numerous challenges. These include delays in clinical trial approvals, the implications of the new pharmaceutical pricing policy, and the need for a uniform code governing sales and marketing practices. Additional concerns such as compulsory licensing issues, manufacturing quality lapses, regulatory ambiguity, reluctance among healthcare providers to prescribe biosimilars, production complexities, and intensifying competition all demand immediate and strategic intervention. Addressing these hurdles is crucial for ensuring sustainable growth and global leadership in the biosimilar space.

VIII. IMPORTANCE OF BIOSIMILARS

A. Increased Access and Affordability

Lower Costs:

Biosimilars are developed to be highly similar to their reference biologic products but are typically produced at a lower cost. This makes them more economical alternatives for patients and healthcare providers.

Broader Patient Access:

The reduced cost of biosimilars expands access to biologic therapies for a larger patient population, particularly in low- and middle-income countries where healthcare resources are limited.

Improved Quality of Life:

By making essential treatments more affordable, biosimilars can enhance the quality of life for patients suffering from chronic conditions such as cancer, rheumatoid arthritis, and autoimmune diseases.

B. Fostering Competition and Innovation

Market Competition:

The entry of biosimilars into the market intensifies competition among biopharmaceutical companies. This often results in further price reductions and drives innovation in therapeutic solutions.

Encouraging Research and Development:

Increased competition from biosimilars motivates companies to invest more in R&D, leading to advancements in clinical outcomes, new biologic developments, and better treatment options.

C. Healthcare System Benefits

Savings and Sustainability:

Cost savings from the use of biosimilars can be reinvested into other areas of healthcare, thereby improving system efficiency and long-term sustainability.

Addressing Budget Constraints:

Many healthcare systems face significant budgetary pressures. Biosimilars provide a cost-effective solution, helping to alleviate financial burdens while maintaining or improving patient care.

IX. ADVANTAGES OF BIOSIMILARS

A. Reduced Costs

Biosimilars are generally more affordable than their reference biologics, as they bypass the extensive R&D expenses associated with the original product. This leads to lower treatment costs for both patients and healthcare systems.

B. Increased Access to Biologic Therapies

Lower pricing makes biologic treatments more accessible to a wider population, enhancing patient access—especially in low-resource settings—and improving overall health outcomes.

C. Enhanced Competition

The introduction of biosimilars promotes market competition, which can lead to further reductions in drug prices and improved accessibility.

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.538
Volume 13 Issue IV Apr 2025- Available at www.ijraset.com

D. Same Efficacy and Safety

Biosimilars are rigorously evaluated by regulatory authorities to ensure they match the reference biologic in terms of safety, efficacy, and quality, providing patients with equally effective treatment options.

E. Faster Development and Approval

By leveraging existing knowledge and data from the reference biologic, biosimilar development is more time- and cost-efficient, leading to quicker regulatory approval and market availability.

F. Improved Healthcare System Sustainability

The cost savings from biosimilars help healthcare systems manage limited budgets more effectively, making care delivery more sustainable in the long run.

G. More Treatment Options

Biosimilars increase the variety of therapeutic options available to clinicians, allowing for more personalized treatment plans tailored to individual patient needs.

X. DISADVANTAGES OF BIOSIMILARS

A. Efficacy and Safety Concerns

- Not Identical to the Original Biologic:While biosimilars are highly similar to their reference biologics, they are not exact copies. Subtle molecular differences may exist due to the complex nature of biologic drugs.
- Potential for Reduced Efficacy: These minor variations could theoretically affect efficacy, although clinical studies typically find no significant differences in outcomes.
- Immunogenicity Risks: Biosimilars may trigger immune responses in some patients, which could lead to adverse reactions or reduced therapeutic effectiveness.
- Switching Concerns: Switching stable patients from a reference biologic to a biosimilar can raise concerns about maintaining efficacy and safety, particularly in sensitive or high-risk populations.
- Uncertain Long-Term Effects: Long-term safety and efficacy data for biosimilars are still evolving, and some uncertainties remain regarding their prolonged use.

B. Manufacturing and Quality Control

- Complex Manufacturing Processes: Producing biosimilars involves intricate biological processes, making it difficult to replicate the original biologic exactly.
- Manufacturing Variability: Small changes in manufacturing conditions can lead to variations in the final product, potentially affecting its safety, efficacy, or immunogenicity.
- Quality Control Challenges: Maintaining consistent quality across batches requires stringent quality control, which can be difficult and resource-intensive for manufacturers.

C. Other Considerations

- Nomenclature and Interchangeability Issues: Naming conventions for biosimilars can be confusing, and uncertainty remains over whether all biosimilars should be considered interchangeable with their reference products.
- Lack of Switching Studies: There is a shortage of robust clinical studies evaluating the outcomes of switching patients between reference biologics and biosimilars, especially in complex therapeutic areas.
- Indication Extrapolation: Some biosimilars are approved for multiple indications based on extrapolation from limited clinical data, raising safety concerns when used for conditions not directly studied.
- Legal and Regulatory Hurdles: Navigating the complex legal and regulatory landscape—including patent litigations and exclusivity rights—can delay market entry and limit biosimilar availability.

©IJRASET: All Rights are Reserved

XI. APPLICATIONS OF BIOSIMILARS

A. Conditions Treated

1. Inflammatory and Autoimmune Diseases

Biosimilars play a crucial role in managing several chronic inflammatory and autoimmune conditions, including:

- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Plaque psoriasis
- Inflammatory bowel disease (IBD)
  - *Crohn's disease*
  - *Ulcerative colitis*
- Granulomatosis with polyangiitis (Wegener's disease)

2. Cancer

Biosimilars are approved for use in:

- Treating specific types of cancers (e.g., breast cancer, colorectal cancer)
- Managing side effects of chemotherapy, such as neutropenia, by supporting blood cell growth

3. Other Chronic Conditions

Biosimilars are also used in the treatment of:

- Chronic skin and bowel diseases
- Arthritis (various forms)
- Kidney disorders
- Diabetes (e.g., insulin biosimilars)
- Macular degeneration

B. How Biosimilars Work

- Therapeutic Equivalence: Biosimilars are designed to be highly similar to their reference biologic products in efficacy, safety, and immunogenicity.
- Interchangeability: Some biosimilars may be approved for interchangeable use, meaning they can be substituted for the reference biologic without compromising clinical outcomes.
- Biological Origin: Like original biologics, biosimilars are produced using living cells, involving complex biotechnological processes.
- Streamlined Clinical Trials: Biosimilars typically require fewer clinical trials than original biologics, relying on existing data to demonstrate similarity. This contributes to lower development costs.
- Regulatory Assurance: Regulatory agencies ensure that biosimilars meet stringent standards for quality, safety, and effectiveness—matching their reference products in real-world performance.

XII. EXAMPLES OF BIOSIMILARS



©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

Drug Product	Company	Reference Product and Sponsor	Marketing Status	FDA Approval Date
Mvasi™ (bevacizumab-awwb)	Amgen Allergan	Genentech/Roche Avastin® (bevacizumab)	Not available	Approved 9/14/2017
Cyltezo™ (adalimumab-adbm)	Boehringer Ingelheim International GmbH	AbbVie Humira® (adalimumab)	Not available	Approved 8/25/2017
Renflexis® (infliximab-abda)	Samsung Bioepis	Janssen Remicade® (infliximab)	Launched July 2017	Approved 4/21/2017
Amjevita® (adalimumab-atto)	Amgen	AbbVie Humira® (adalimumab)	Not Available	Approved 9/23/2016
Erelzi ® (etanercept-szzs)	Sandoz	Amgen Embrel® (etanercept)	Not Available	Approved 8/30/2016
Inflectra® (infliximab-dyyb)	Celltrion	Janssen Remicade® (infliximab)	Launched Nov. 2016	Approved 4/05/2016
Zarxio® (filgrastim-sndz)	Sandoz	Amgen Neupogen® (filgrastim)	Launched Sept. 2015	Approved 03/06/2015

XIII. FUTURE PERSPECTIVE OF BIOSIMILARS

A. *Market Growth and Trends*

- Global Expansion: The biosimilars market is poised for robust growth, expected to rise from USD 23.96 billion in 2023 to USD 73.03 billion by 2030, at a CAGR of 17.3%.
- India's Emergence: India stands out with immense potential to lead in biosimilar production and adoption. The Indian biosimilar market is forecasted to reach USD 2,108 million by 2030, growing at a CAGR of 25.2% from 2022.

B. *Innovation in Biosimilars*

- Next-Generation Biosimilars: Future development will focus on enhanced efficacy, safety, and patient convenience, supported by sustainable manufacturing and personalized medicine.

C. *Strategic Market Drivers*

- Patent Expirations: The upcoming expiry of biologic patents opens a significant window for biosimilar developers to enter the market with new alternatives.
- Competitive Landscape: An increasing number of biosimilars will intensify market competition, resulting in lower treatment costs and broader patient access.

D. *Regulatory and Clinical Efficiency*

- Extrapolation of Indications: The practice of indication extrapolation allows biosimilars to be approved for multiple uses based on fewer clinical trials, reducing development time and costs.

©IJRASET: All Rights are Reserved

XIV. CHALLENGES AND CONSIDERATIONS IN BIOSIMILAR DEVELOPMENT AND ADOPTION

1. Regulatory Hurdles
   - Complex Regulatory Landscape: Varying global regulations, stringent manufacturing standards, and intellectual property issues—especially in gene therapy biosimilars—pose significant barriers to market entry.
2. Manufacturing and Supply Chain
   - Production Complexity: Biosimilars require highly controlled manufacturing environments.
   - Supply Chain Reliability: Ensuring consistent production and distribution is vital to avoid shortages that can affect patient safety and treatment outcomes.
3. Pharmacovigilance
   - Post-Market Surveillance: Due to potential minor variations in structure or composition, rigorous pharmacovigilance is essential to monitor safety and long-term efficacy.
4. Interchangeability and Insurance Dynamics
   - Adoption Dependent on Interchangeability: Although it can drive usage and affordability, interchangeability depends on regulatory approvals and formulary inclusion by insurers, which may limit patient choice.
5. Patient Access and Affordability
   - Barriers to Access: Despite lower costs compared to biologics, pricing policies, reimbursement delays, and healthcare inequalities may still hinder universal patient access.
6. Awareness Among Healthcare Providers
   - Educational Gaps: Lack of understanding among physicians and pharmacists regarding biosimilar efficacy, development, and safety can slow adoption. Enhanced training and communication are crucial.

XV. CONCLUSION

Biosimilars offer significant promise in enhancing patient accessibility to effective treatments for both malignant and nonmalignant conditions by substantially lowering therapy costs. Since the introduction of the first biosimilar, the development and application of these “similar biologics” have expanded rapidly. Regulatory agencies across the globe are increasingly approving biosimilars for a broad spectrum of cancerous and noncancerous diseases each year.

India has emerged as a prominent global hub for the development and manufacturing of biosimilars. With a large and growing population, the country also represents a vast market for these cost-effective therapies. However, despite the tremendous potential and high expectations, India faces considerable challenges in sustaining its leadership position.

To fully realize this potential and continue as a global leader, Indian biopharmaceutical companies must invest in technological advancements and workforce upskilling. Achieving these goals will require a supportive ecosystem, including proactive engagement and facilitation from government bodies and regulatory authorities.


REFERENCES

[1] Kefalas CH, Ciociola AA, and the FDA-Related Matters Committee of the American College ofGastroenterology. The FDA's Generic-Drug Approval Process: Similarities to Differences fromBrand-Name Drugs. Am J Gastroenterol 2011;106:1018–1021.
[2] European Medicines Agency. Guideline on Similar Biological Medicinal Products [draft] .http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500142978.pdf. Draft overarching guidelines on biosimilars (reference number CHMP/437/04 Rev1). Published May 22, 2013. Accessed December 1, 2015.
[3] Mellstedt, H., et. al. The challenge of biosimilars. Annals of Oncology 19. March 2008, pp. 411-419.European Medicines Agency. Questions and answers on biosimilar medicines (similar biologicalmedicinal products).
[4] http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf. Published September 27, 2012. Accessed December 1, 2015.
[5] Camacho LH, Frost CP, Abella E, et al. Biosimilars 101: considerations for U.S. oncologists inclinical practice. Cancer Med. 2014;3:889-899.
[6] Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol.2012;7(Suppl 1):29-34.
[7] Karri Siva Durga and M. Swapna. (2022). Biosimilars: Regulations and Emerging Market Needs. World Journal of Pharmacy and Pharmaceutical Sciences, ISSN 2278 – 4357, Volume 11, Issue 12, 871-887
[8] Guidance for Industry. (2022). Preparation of Quality Information for Drug submission for New Approval: Biotechnological/ Biological products. Central Drugs Standard Control Organization. CT/71108. Version 1.1
[9] World Health Organization. (2021). Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs).
[10] ICH Q1 A(R2)- Stability Testing of New Drug Substances and Products
[11] ICH guideline on preclinical safety evaluation of biotechnology-derived pharmaceuticals (S6)

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |

[12] World Health Organization (WHO), (2013). Guidelines on the quality, safety and efficacy of bio-therapeutic protein products prepared by recombinant DNA technology.
[13] Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India, 2016
[14] K.K. Tripathi. Regulatory Approaches and criteria for approvals of Biotech medicines in India.
[15] The Drugs and Cosmetics Act 1940 and Drugs rules, 1945.
[16] Special report by BIRAC, India: The emerging hub for biologics and biosimilars.
[17] Biosimilar and Interchangeable Products – FDA (2017). Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
[18] Biosimilars Market Global Scenario, Market Size, Outlook and Trend. (2018). Available from:https://www.variantmarketresearch.com/report-categories/.../biosimilars-market
[19] Biosimilars Market Segmentation by Product Type, Global Demand Analysis & Opportunity. (2019). Available from: https://www.researchnester.com/
[20] Biotechnology industry in India – Market Share, Reports, Growth (2017). Available from: https://www.ibef.org
[21] Indian biosimilar market to be worth $40 billion by 2030. (2016). Available from: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-biosimilars-market-may-reach-40-bn-by-2030-report/articleshow/54717517.cms?from=mdr
[22] Indian Biosimilars Industry-Roadmap to Actualize Global Leadership. Confederation of Indian Industry & Sathguru Management Consultants. (2018). Available from: https://www.sathguru.com
[23] Biologicals [Internet]. [cited 2023 Aug 21]. Available from: https://cdsco.gov.in/opencms/opencms/en/biologicals/
[24] Development of Biosimilars: An Overview of The Regulatory Framework In India, Usa, Eu; Major Challenges And Related Case Studies | International Journal of Pharmaceutical Sciences And Research [Internet]. [cited 2023 Sep 7]. Available from: https://ijpsr.com/bft-article/development-of-biosimilars-an-overview-of-the-regulatory-framework-in-india-usa-eu-major-challenges-and-related-case-studies/
[25] Healthcare Providers (Biologics) | FDA [Internet]. [cited 2023 Aug 28]. Available from: https://www.fda.gov/vaccines-blood-biologics/resources-you-biologics/healthcare-providers-biologics
[26] Blackstone EA, Fuhr JP. The Economics of Biosimilars. Am Health Drug Benefits [Internet]. 2013 Sep [cited 2023 Feb 15];6(8):469. Available from: /pmc/articles/PMC4031732/

©IJRASET: All Rights are Reserved | SJ Impact Factor 7.538 | ISRA Journal Impact Factor 7.894 |



10.22214/IJRASET

45.98

IMPACT FACTOR: 7.129

IMPACT FACTOR: 7.429

INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 (24*7 Support on Whatsapp)